Synthesis, HIV-RT inhibitory activity and SAR of 1-benzyl-1H-1,2,3-triazole derivatives of carbohydrates.

This paper describes the synthesis of several 1-benzyl-1H-1,2,3-triazoles attached to different carbohydrate templates and their in vitro inhibitory profile against HIV-1 reverse transcriptase. In addition a theoretical comparison of the most active compounds with other classical antivirals was also performed. Our results showed 2a, 2d and 2g as the most active compounds that inhibited the HIV-1 reverse transcriptase catalytic activity with cytotoxicity lower than AZT and SI higher than DDC and DDI. The overall theoretical analysis of the molecular descriptors of 2a, 2d and 2g revealed that their HOMO energy is similar to other antivirals in use (AZT, DDC, DDI and 3TC) and together with the volume may contribute for the biological profile as they may allow new interactions with the target. In fact the 1,2,3-triazole compounds presented more lipophilicity and higher molecular volume and weight than the antivirals studied, which suggested that these features might not only contribute for new interactions with the HIV-RT but also influence the specificity and consequently the low cytoxicity profile of these compounds. Thus these data point them as promising leading compounds for generating new anti-HIV-RT compounds.

[1]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[2]  H. Castro,et al.  Synthesis, in vitro evaluation, and SAR studies of a potential antichagasic 1H-pyrazolo[3,4-b]pyridine series. , 2007, Bioorganic & Medicinal Chemistry.

[3]  Joseph Quinn,et al.  Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults , 2001, AIDS.

[4]  Anna E Speers,et al.  Profiling enzyme activities in vivo using click chemistry methods. , 2004, Chemistry & biology.

[5]  Anna E Speers,et al.  Activity-based protein profiling in vivo using a copper(i)-catalyzed azide-alkyne [3 + 2] cycloaddition. , 2003, Journal of the American Chemical Society.

[6]  B. Cooper,et al.  1-(Fluorobenzyl)-4-amino-1H-1,2,3-triazolo[4,5-c]pyridines: synthesis and anticonvulsant activity. , 1995, Journal of medicinal chemistry.

[7]  E. Albuquerque,et al.  Design, synthesis and pharmacological profile of novel dopamine D2 receptor ligands. , 2003, Bioorganic & medicinal chemistry.

[8]  A. Akar,et al.  Synthesis and investigation of tuberculosis inhibition activities of some 1,2,3-triazole derivatives. , 2003, European journal of medicinal chemistry.

[9]  R. Micetich,et al.  Synthesis and beta-lactamase inhibitory properties of 2 beta-[(1,2,3-triazol-1-yl)methyl]-2 alpha-methylpenam-3 alpha-carboxylic acid 1,1-dioxide and related triazolyl derivatives. , 1987, Journal of medicinal chemistry.

[10]  B. Haynes,et al.  Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. , 1984, Science.

[11]  E. De Clercq,et al.  1,2,3-Triazole-[2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D- ribofuranosyl]-3'-spiro-5"-(4"-amino-1",2"-oxathiole 2",2"-dioxide) (TSAO) analogues: synthesis and anti-HIV-1 activity. , 1994, Journal of medicinal chemistry.

[12]  Carlos R Rodrigues,et al.  Synthesis, tuberculosis inhibitory activity, and SAR study of N-substituted-phenyl-1,2,3-triazole derivatives. , 2006, Bioorganic & medicinal chemistry.

[13]  T. Seo,et al.  Click chemistry to construct fluorescent oligonucleotides for DNA sequencing. , 2003, The Journal of organic chemistry.

[14]  Russolina B Zingali,et al.  Antiplatelet properties of novel N-substituted-phenyl-1,2,3-triazole-4-acylhydrazone derivatives. , 2003, Bioorganic & medicinal chemistry.

[15]  Arun K. Ghosh,et al.  Development of protease inhibitors and the fight with drug-resistant HIV-1 variants. , 2008, Advances in pharmacology.

[16]  Qian Wang,et al.  Bioconjugation by copper(I)-catalyzed azide-alkyne [3 + 2] cycloaddition. , 2003, Journal of the American Chemical Society.

[17]  V. Ferreira,et al.  SYNTHESIS OF 4-ACYL-1H-1,2,3-TRIAZOLIC NUCLEOSIDES , 2001, Nucleosides, nucleotides & nucleic acids.

[18]  R. Siliciano,et al.  The challenge of viral reservoirs in HIV-1 infection. , 2002, Annual review of medicine.

[19]  D. Tirrell,et al.  Cell surface labeling of Escherichia coli via copper(I)-catalyzed [3+2] cycloaddition. , 2003, Journal of the American Chemical Society.

[20]  C. Leport,et al.  Evolution of Protease and Reverse Transcriptase Inhibitor Resistance-Associated Mutations in HIV-1-Infected Protease Inhibitor-Treated Patients with Persistent Low Viraemia , 2005, Antiviral therapy.

[21]  J. Chermann,et al.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). , 1983, Science.

[22]  S. Kalichman,et al.  Human Immunodeficiency Virus Viral Load in Blood Plasma and Semen: Review and Implications of Empirical Findings , 2008, Sexually transmitted diseases.

[23]  K. Kent,et al.  Practical synthesis of the anti-HIV drug, PMPA , 1998 .

[24]  Li,et al.  Transport, metabolism and elimination mechanisms of anti-HIV agents. , 1999, Advanced drug delivery reviews.

[25]  M. Wolff,et al.  BURGER'S MEDICINAL CHEMISTRY AND DRUG DISCOVERY , 1996 .

[26]  A. Akar,et al.  Diazoaldehyde Chemistry. Part 3. Synthesis of 4-acyl-1H-1,2,3-triazole derivatives† , 1996 .

[27]  Erik De Clercq,et al.  New developments in anti-HIV chemotherapy , 2001 .

[28]  Z. Arnold,et al.  Synthetic reactions of dimethylformamide. XXIII. Formylation of some aliphatic diazo compounds , 1967 .

[29]  Chi‐Huey Wong,et al.  A Potent and Highly Selective Inhibitor of Human α-1,3-Fucosyltransferase via Click Chemistry , 2003 .

[30]  E. Clercq.  Antiviral drugs: current state of the art. , 2001, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[31]  A. Tanuri,et al.  Estratégias farmacológicas para a terapia anti-AIDS , 2002 .

[32]  E. D. Clercq.  Structures et activités des inhibiteurs non-nucléosidiques de la transcriptase inverse du VIH (INNTI) , 2000 .

[33]  P. Taylor,et al.  Click chemistry in situ: acetylcholinesterase as a reaction vessel for the selective assembly of a femtomolar inhibitor from an array of building blocks. , 2002, Angewandte Chemie.

[34]  M. G. Albuquerque,et al.  HIV-1 reverse transcriptase: a therapeutical target in the spotlight. , 2006, Current medicinal chemistry.

[35]  A. J. Bortoluzzi,et al.  Applying click chemistry to synthesis of chiral [1,2,3]‐triazole liquid crystals , 2005 .

[36]  S. Inouye,et al.  Specificity of priming reaction of HIV-1 reverse transcriptase, 2'-OH or 3'-OH. , 1994, The Journal of biological chemistry.

[37]  E. Pedersen,et al.  Non-Nucleoside Reverse Transcriptase Inhibitors: The NNRTI Boom , 1999, Antiviral chemistry & chemotherapy.

[38]  E. Clercq.  New approaches toward anti-HIV chemotherapy. , 2005 .

[39]  G. Romeiro,et al.  A new and efficient procedure for preparing 1,2,3-triazoles , 1997 .